CEBPA and acute myeloid leukemia: The number of patients diagnosed as ‘AML with CEBPA mutation’, including both biallelic mutations and single mutations located in the basic leucine zipper (bZIP) region, was increased to 65 (7.5%) according to WHO2022, representing an additional 8 patients compared to 57 (6.6%) who were diagnosed as ‘AML with biallelic mutations of CEBPA’ according to WHO2016.